Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study
Article first published online: 4 MAR 2003
Acta Neurologica Scandinavica
Volume 107, Issue 3, pages 207–210, March 2003
How to Cite
Monte, T. L., Rieder, C. R. M., Tort, A. B., Rockenback, I., Pereira, M. L., Silveira, I., Ferro, A., Sequeiros, J. and Jardim, L. B. (2003), Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurologica Scandinavica, 107: 207–210. doi: 10.1034/j.1600-0404.2003.02132.x
- Issue published online: 4 MAR 2003
- Article first published online: 4 MAR 2003
- Accepted for publication July 22, 2002
- Machado-Joseph disease;
- polyglutamine diseases;
- serotoninergic system;
- spinocerebellar ataxias
Context – Machado-Joseph Disease (MJD/SCA3) is an autosomal dominant spinocerebellar degeneration that evolves to disability and death. Experimental data have shown that serotonin is an important cerebellar neurotransmitter and that impairment of the serotoninergic cerebellar system can induce cerebellar ataxia.
Objectives – To evaluate the efficacy of fluoxetine, a serotonin reuptake inhibitor, in treating neurologic dysfunction in patients with MJD.
Patients and methods – Thirteen MJD patients were treated with fluoxetine (20 mg/day) and were followed-up for 6 weeks. Outcome measures included functional capacity, standardized neurologic and cognitive ratings. The Montgomery-Asberg depression rating scale was used to control depressive symptoms.
Results – There was no significant improvement in motor abilities after 6 weeks of treatment.
Conclusions – These results suggest that fluoxetine has no benefit in motor function of patients with MJD/SCA3.